NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has signed an agreement with Bayer Pharma for the use of Horizon's Genesis genome editing technology in support of Bayer's cancer R&D programs.

Horizon will use its platform to develop human isogenic cell lines for use in Bayer's programs in order to deliver cell lines that more accurately model the disease-relevant mutations found in human tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.